Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge

Full text
Cazarim, Maurilio de Souza [1] ; de Freitas, Osvaldo [1] ; Penaforte, Thais Rodrigues [2] ; Achcar, Angela [3] ; Leira Pereira, Leonardo Regis [1, 4]
Total Authors: 5
[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Fed Bahia, Sch Pharm, Dept Med, Salvador, BA - Brazil
[3] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Social Med, BR-14049 Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Ctr Pesquisa Assistencia Farmaceut & Farm Clin CP, 23 Blc S, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PLoS One; v. 11, n. 6 JUN 15 2016.
Web of Science Citations: 5

Introduction Almost 50% of the 17.5 million deaths worldwide from cardiovascular disease have been associated with systemic arterial hypertension (SAH). Into this scenario, Pharmaceutical Care (PC) has been inserted in order to improve the management of SAH and reduce its risks. Objective To evaluate the outcomes and healthcare assistance achieved after discharge of hypertension patients from the PC program. Methods This is a quasi-experimental study with historical controls. Retrospective data collection from 2006 to 2012 was begun in 2013 and included a PC program performed over one year. PC was performed in two basic units of the public health systemin Ribeirao Preto-SP, Brazil, where the pharmacist followed up 104 hypertensive patients. The clinical indicators of systolic (SBP) and diastolic blood pressure (DBP), triglycerides, total-cholesterol, high and low density lipoprotein cholesterol were collected, as well as care indicators related to the number of consultations (basic, specialized and emergency care) and antihypertensive drugs used. The coronary risk of patients by the Framingham risk score was also calculated. For the analysis, the data were divided into three periods, 2006-2008 as pre-PC, 2009 as PC and 2010-2012 as post-PC. Results In the pre-PC period, 54.4%, 79.0% and 27.3% of patients presented satisfactory levels of SBP, DBP and total-cholesterol, respectively. In the post-PC period, the percentages were 93.0% for SBP and DBP {[}p < 0.001] and 60.6% for total-cholesterol {[}p < 0.001]. The average number of consultations per patient/year in primary care was 1.66 +/- 1.43 and 2.36 +/- 1.73, {[}p = 0.012]; and for emergency care was 1.70 +/- 1.43 and 1.06 +/- 0.81, {[}p = 0.002] in the pre-PC and post-PC periods, respectively. The pre-PC Framingham risk in the last year was 14.3% +/- 10.6 and the average post-PC was 10.9% +/- 7.9. Conclusion PC was effective in the control of blood pressure and total-cholesterolafter discharge of the hypertensive patients from PC program. (AU)

FAPESP's process: 07/06514-5 - Pharmaceutical Care on Hypertension : clinical impact, economic and social
Grantee:Thais Rodrigues Penaforte
Support type: Scholarships in Brazil - Doctorate